CI-AKI
Conditions
Interventions
Study Group (Start taking daglipzin at least 1 week (=7 days) before coronary angiography):None
Control Group (No SGLT-2 inhibitors of any kind were taken 1 week (=7 days) before coronary angiography):None
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1)? coronary angiography, including PCI, CAG and CCTA, has been performed; And the medical records are shown as follows: ?=18 and =100 years old, male or female; ? Patients with CSS combined with T2DM; Start taking daglipzin at least 1 week (= 7 days) before coronary angiography (study group) or have not taken SGLT-2i of any kind in the previous 1 week (= 7 days) (control group); ? Normal liver function or mild injury (alanine aminotransferase = 1.5 times the upper limit of normal); (5) Normal renal function or mild to moderate impairment (glomerular filtration rate = 45 mL/min/1.73m²); 2) Agree to sign informed consent and cooperate with relevant tests, inspections and follow-up.
Exclusion criteria
Exclusion criteria: 1) Suffering from serious diseases, such as malignant tumors, organ failure caused by various reasons, severe immune system diseases, hemodynamic instability, severe infections, etc.; 2) Taking drugs with obvious renal toxicity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CI-AKI events were recorded within 48 hours (KDIGO criteria) after the administration of contrast media;CI-AKI events at 72 h (ESUR criteria) after the administration of contrast media; | — |
Countries
China
Contacts
Public ContactZinan ZHAO
Beijing Hospital
Outcome results
None listed